Figure 8.

Improvements in markers of (A and B) renal function, (C) serum cholesterol and (D) oxidative stress in patients with chronic kidney disease and dyslipidaemia after treatment with 2 mg pitavastatin daily alone, or in combination with 10 mg ezetimibe, for 6 months. 8-hydroxy-2′-deoxyguanosine and L-fatty acid binding protein were measured enzymatically using enzyme-linked immunosorbent assays, proteinuria was measured using a pyrogallol red method and LDL-C concentrations were calculated using Friedewald's formula. *P < 0.001 vs. before pitavastatin treatment, †P < 0.001 vs. before pitavastatin + ezetimibe treatment, ‡P < 0.05 vs. after pitavastatin treatment alone. Data from Nakamura et al. [112]. Before (□); After (). 8-OHdG,8-hydroxy-2′-deoxyguanosine; LDL-C, low density lipoprotein cholesterol; L-FABP, L-fatty acid binding protein